David A. Siegel Cabaletta Bio, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 72,500 shares of CABA stock, worth $363,225. This represents 0.0% of its overall portfolio holdings.
Number of Shares
72,500Holding current value
$363,225% of portfolio
0.0%Shares
11 transactions
Others Institutions Holding CABA
# of Institutions
145Shares Held
50.1MCall Options Held
19.9KPut Options Held
41.5K-
Jennison Associates LLC5.55MShares$27.8 Million0.03% of portfolio
-
Black Rock Inc. New York, NY4.76MShares$23.8 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.88MShares$19.4 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.04MShares$15.2 Million0.04% of portfolio
-
Alkeon Capital Management LLC New York, NY2.62MShares$13.1 Million0.03% of portfolio
About Cabaletta Bio, Inc.
- Ticker CABA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,014,000
- Market Cap $145M
- Description
- Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...